SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing intense investor frustration as the stock continues a sharp, multi-week decline that has decoupled from broader market gains. The community is actively debating whether this represents an oversold buying opportunity, a structural shift due to mounting AI infrastructure costs and integration concerns, or deliberate algorithmic manipulation.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech100 is drawing significant attention as retail investors rotate into the stock to gain exposure to high-profile private companies like SpaceX and Anthropic ahead of potential IPOs. Community sentiment is driven by a mix of speculative trading momentum, discussions around the fund's portfolio concentration compared to peers, and anticipation that share scarcity could spark a rapid move toward historical highs.

The Shrimp Army

SHRIMPS is gaining traction as part of a broader trend of aquatic-themed memecoins, with investors debating the potential for rapid gains versus the volatility typical of highly speculative pump-and-dump cycles. The community remains focused on momentum-driven price action and the ability to maintain current levels while comparing the token to other recent market participants in the sector.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is currently the center of intense debate as traders react to a significant business model shift involving the launch of an in-house AGI CPU, with the community split between bullish sentiment over long-term AI-driven revenue growth and skepticism regarding the stock's valuation. Investors are actively discussing the potential for market share gains in the data center space, while some bears caution against chasing the stock due to lofty expectations and broader semiconductor sector volatility.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is facing intense volatility following a highly critical report from Culper Research that alleges the company is engaging in channel stuffing and misleading financial reporting. While the stock has seen a sharp sell-off, the community is deeply divided, with many long-term shareholders dismissing the report as a tactical short-seller attack and urging management to provide a more aggressive, detailed rebuttal to restore market confidence.

PRIME is the native token of the Echelon Prime Foundation, a Web3 ecosystem advancing the next generation of gaming. Echelon creates and distributes tools to encourage innovation in, and promote the growth of, novel gaming models and economies. The first game to adopt and utilize PRIME is Parallel, a sci-fi trading card game.

Echelon Prime

Echelon Prime is trending as community members highlight its role as the backbone of on-chain gaming economies, driving speculation about a potential rally fueled by the broader recovery in altcoins. Investors are actively debating accumulation strategies and technical breakouts while looking for signs that the token is poised for a significant move amid the expanding Web3 gaming sector.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is currently the focal point of intense market debate as investors grapple with its aggressive capital-raising strategy and heavy reliance on Bitcoin accumulation. The community is sharply divided, with bulls pointing to the company's long-term Bitcoin treasury strategy as a high-conviction play, while skeptical traders and bears emphasize the risks of ongoing share dilution and the stock's high volatility relative to broader market movements.

Fundrise Growth Tech Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is trending as investors react to extreme price volatility and speculative momentum, fueled by the fund's heavy exposure to private AI and space exploration leaders like OpenAI, Anthropic, and SpaceX. The community is intensely debating whether the current premium to net asset value represents a historic opportunity or a classic bubble, with many actively rotating capital into similar vehicles like DXYZ and ORBS to gain comparable exposure at more favorable valuations.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron shares are under intense pressure as algorithmic traders react to a Google research announcement regarding an AI memory compression algorithm, while investors continue to weigh the impact of the company's large-scale debt repurchase plan. The community is deeply divided between those viewing the pullback as a buying opportunity given the firm's strong fundamentals and those fearing that recent headline-driven volatility signals a potential cyclical peak.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is currently experiencing extreme volatility following a disappointing earnings report and significant insider share sales by CEO Lourenco Goncalves, which has fueled widespread anxiety regarding debt levels and the viability of the long-anticipated POSCO partnership. While bears warn of structural weakness and potential bankruptcy risks, a vocal segment of the retail community is aggressively buying the dip, labeling the sell-off as a manipulative shakeout and pointing to the company's domestic steel moat and HRC pricing as reasons for an inevitable rebound.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing

In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $58.94, denoting a +2.7% move from the preceding trading day.

Will the Recent Label Expansion of BMY's Opdivo Boost Its IO Franchise?

Bristol Myers Squibb's Opdivo expansions highlight pharma companies' push to grow oncology franchises amid rising competition and pipeline innovation.

Procyon Advisors LLC Sells 20,349 Shares of Bristol Myers Squibb Company $BMY

Procyon Advisors LLC trimmed its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 56.8% during the fourth quarter, according to the company in its most recent 13F filing with the...

E. Ohman J or Asset Management AB Buys 46,000 Shares of Bristol Myers Squibb Company $BMY

E. Ohman J or Asset Management AB boosted its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 183.2% during the fourth quarter, according to its most recent Form 13F filing with the...

<ul class="summary-bullets"><li>Founder Patrick Soon-Shiong said Abraxane from Bristol Myers Squibb could help boost immune responses when combined with the company’s cancer immunotherapy Anktiva.</li><li>Founder Patrick Soon-Shiong said Abraxane may help “expose” tumors through immune-activating signals and support macrophage activity.</li><li>Anktiva was recently added to Macau’s approved drug list and included by the National Comprehensive Cancer Network for certain bladder cancer patients.</li></ul>Shares of ImmunityBio, Inc. (IBRX)&nbsp;rose over 1% in premarket trading on Tuesday after a newly posted Phase 1 study showed its cancer therapy Anktiva is being tested alongside Bristol Myers Squibb’s Abraxane and other drugs in patients with pancreatic cancer ahead of surgery.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> jumped nearly 11% on Monday, marking its best session in a month.<h2 class="st-heading-2">Phase 1 Trial Tests Anktiva In Pancreatic Cancer</h2>According to a new regulatory update on Monday, the open-label Phase 1 study is evaluating Anktiva in combination with the investigational agents Sotevtamab and Zabadinostat, plus the chemotherapy drugs Gemcitabine and Abraxane, in participants with borderline resectable or locally advanced pancreatic ductal adenocarcinoma.The treatment is being given before surgery, followed by tumor removal and additional immunotherapy afterward, as researchers evaluate the safety and early signals of effectiveness of the combination approach.Participants enrolled in the study will undergo endoscopic ultrasound-guided biopsies of the primary tumor within seven days before treatment begins. Samples will be used for diagnostic evaluation and stored in an approved tissue bank.<h2 class="st-heading-2">Bristol Myers’ Abraxane May Support Anktiva</h2>Soon-Shiong&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2036321510348947567">said on X</a> that Abraxane differs from older chemotherapy agents such as Taxol because it is delivered using albumin, a naturally occurring protein that helps transport the drug across blood vessel walls into the tumor microenvironment.He said the drug enters tumors through a natural transport pathway called GP60 and helps activate macrophages to attack cancer cells while also “exposing” tumors through DAMP signaling, making them easier for natural killer (NK) cells and T cells to recognize and destroy.“So it’s not that we ignore the use of chemo, it’s how we use it to activate the immune system while protecting and activating the lymphocytes with Anktiva,” Soon-Shiong said. Abraxane was originally developed by Abraxis BioScience, which Soon-Shiong founded, and is now marketed by Bristol Myers Squibb for breast, lung and pancreatic cancers.<h2 class="st-heading-2">Anktiva Platform Therapy Strategy Gains Support</h2>The development adds to ImmunityBio’s broader effort to position Anktiva as a platform immunotherapy that works alongside vaccines, checkpoint inhibitors and chemotherapy backbones across multiple cancer types rather than as a standalone treatment.Last week, Soon-Shiong pointed to&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-premarket-early-anktiva-immune-data-macau-nod-bull-case/cZ3Xl3sRILc">early immune data</a> from the first 20 participants in an Anktiva study showing increases in absolute lymphocyte counts when the therapy was used with the company’s adenovirus-based cancer vaccine. The trial has enrolled 138 patients randomized to the combination or placebo.He said baseline lymphocyte levels typically decline with age but appeared to increase with Anktiva in the early analysis, supporting the therapy’s immune-stimulating role.<h2 class="st-heading-2">Anktiva Gains Macau Listing, NCCN Backing</h2>Momentum around Anktiva has also been driven by recent regulatory developments, including its addition to&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-snap-losing-streak-anktiva-macau-drug-list/cZ3XLBrRIhU">Macau’s approved</a> drug list for bladder cancer. Anktiva now stands alongside therapies from Bristol Myers Squibb, Eli Lilly, Vertex Pharmaceuticals, Gilead Sciences and Moderna in Macau.&nbsp;In the U.S., the National Comprehensive Cancer Network (NCCN) added Anktiva with BCG as an “other recommended” option for papillary bladder cancer that no longer responds to standard BCG treatment, expanding its positioning beyond carcinoma in situ under treatment guidelines.ImmunityBio has also resubmitted its application seeking to expand Anktiva’s label to papillary bladder cancer after previously receiving a refusal-to-file letter from regulators.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for IBRX has slipped to ‘bearish’ levels over the past week from the ‘extremely bullish’ zone amid ‘low’ message volumes over the last 24-hours.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_ss_png_68b9bc5725.webp" alt="ibrx ss.png" width="973" height="145"><figcaption>IBRX sentiment and message volume as of March 24 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/PureLand/message/648355601">said</a> IBRX shares showed signs of steady accumulation after closing near session highs and, citing recent regulatory and guideline momentum. They expect the stock to climb toward $20 by Friday.<stembedurl>https://stocktwits.com/PureLand/message/648355601</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Dirk1969/message/648354937">said</a> IBRX is “currently the best stock with the most potential.”<stembedurl>https://stocktwits.com/Dirk1969/message/648354937</stembedurl>IBRX stock has surged nearly 250% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ImmunityBio logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

IBRX Stock Rises Premarket: Anktiva Moves Into Pre-Surgery Pancreatic Cancer Combo Trial With Bristol Myers Drug

The comments come amid the firm’s strategy to position Anktiva as a platform immunotherapy that works along with vaccines, checkpoint inhibitors and chemotherapy.

Equity

Diversified Trust Co. Has $6.82 Million Stock Holdings in Bristol Myers Squibb Company $BMY

Diversified Trust Co. grew its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 25.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 126,336 shares of the biopharmaceutical company's stock a...

FDA Approves BMY's Opdivo Label Expansion in Classical Hodgkin Lymphoma

Bristol Myers expands Opdivo's reach with new U.S. and EU approvals in Hodgkin lymphoma, strengthening its immunotherapy leadership and growth outlook.

Can Anktiva's Label Expansion Unlock the Next Growth Phase for IBRX?

ImmunityBio bets on Anktiva label expansion to drive growth, but intense Big Pharma competition and premium valuation raise questions about its next phase.

Wealth Enhancement Advisory Services LLC Purchases 318,898 Shares of Bristol Myers Squibb Company $BMY

Wealth Enhancement Advisory Services LLC raised its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 26.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,533,355 shares of the biopharmaceutica...

Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of new clinical trial and real-world data for Camzyos (mavacamten) at the American College of Cardiologys (ACC) Annual Scientific...

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Current Price	$58.94
Prev Close	$57.39
Open	$57.79
Dividend Yield	4.62%
50-Day Moving Average	$58.65
Beta	0.32
Avg. Volume	13.86M
PE Ratio	17.04

52-Week High	$62.89
52-Week Low	$42.52
Market Capitalization	$120.03B
EPS (Annual)	$3.46
Price to Book	6.50
Revenue Per Employee	$1.48M

BMY
Bristol-Myers Squibb Co.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BMY News

BMYBristol-Myers Squibb Co.